Valuation: CSL Limited

Market Cap 67.6B 60.35B 55.38B 50.38B 94.46B 6,400B 96.34B 662B 267B 3,378B 254B 248B 10,669B P/E 2027 *
23.3x
P/E 2028 * 21x
Enterprise Value 76.82B 68.58B 62.93B 57.25B 107B 7,272B 109B 752B 303B 3,838B 288B 282B 12,124B EV / Sales 2027 *
4.88x
EV / Sales 2028 * 4.69x
Free-Float
99.97%
Yield 2027 *
2.13%
Yield 2028 * 2.26%
1 day+0.21%
1 week+2.27%
Current month+0.21%
1 month+12.86%
3 months+63.46%
6 months+61.13%
Current year+16.51%
1 week 192.67
Extreme 192.67
202.85
1 month 175
Extreme 175
202.85
Current year 90
Extreme 90
202.85
1 year 90
Extreme 90
202.85
3 years 90
Extreme 90
313.55
5 years 90
Extreme 90
319.78
10 years 90
Extreme 90
342.75
Manager TitleAgeSince
Chief Executive Officer 63 2026-02-10
Director of Finance/CFO 52 2025-10-06
Chief Operating Officer - 2025-04-30
Director TitleAgeSince
Director/Board Member 72 2018-10-16
Director/Board Member 70 2011-02-01
Director/Board Member 71 2019-12-08
Date Insider Type Main position Quantity % Market Cap. Importance
8/26/26 Free

Director

523 0.0001%
8/26/26 Free 317 0.0001% -
8/26/26 Free

Director

1,586 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
+0.21%+2.27%+12.69%-14.39% 67.63B
-0.46%+10.31%+57.38%+143.15% 1,263B
-0.97%+1.60%+45.26%+80.09% 658B
-2.05%+0.73%+36.27%+101.62% 521B
-1.54%+0.18%+53.06%+66.79% 391B
-0.78%+5.51%+79.85%+44.25% 369B
-1.69%+3.17%+32.18%+55.35% 307B
-0.72%+7.83%+12.10%+33.76% 290B
-0.12%+4.68%+57.09%+74.59% 252B
-0.21%+7.34%+39.56%+109.69% 212B
Average -0.71%+5.51%+42.54%+69.49% 432.96B
Weighted average by Cap. -0.80%+6.53%+48.12%+91.61%

Financials

2027 *2028 *
Net sales 15.75B 14.07B 12.91B 11.74B 22.01B 1,491B 22.45B 154B 62.14B 787B 59.13B 57.87B 2,486B 16.31B 14.56B 13.36B 12.16B 22.79B 1,544B 23.24B 160B 64.34B 815B 61.21B 59.91B 2,574B
Net income 2.82B 2.52B 2.31B 2.1B 3.94B 267B 4.02B 27.57B 11.11B 141B 10.57B 10.35B 445B 3.14B 2.81B 2.58B 2.34B 4.39B 298B 4.48B 30.77B 12.4B 157B 11.8B 11.55B 496B
Net Debt 9.22B 8.23B 7.55B 6.87B 12.88B 873B 13.13B 90.19B 36.36B 461B 34.59B 33.85B 1,455B 8.82B 7.88B 7.23B 6.57B 12.32B 835B 12.57B 86.32B 34.79B 441B 33.1B 32.4B 1,392B
Projected Income Statement - Annual - CSL Limited
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,000
Date Price Change Volume
26-11-02 A$201.16 +0.21% 719,742
26-10-30 A$200.73 +1.64% 1,374,203
26-10-29 A$197.50 +0.20% 924,119
26-10-28 A$197.10 +0.16% 1,218,969
26-10-27 A$196.78 +0.84% 1,202,000
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - CSL Limited
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
141.16USD
Average target price
133.90USD
Spread / Average Target
-5.14%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - CSL Limited